Anticoagulants Market Report 2026

Anticoagulants Market Overview

• Anticoagulants market size has reached to $53.88 billion in 2025 • Expected to grow to $97.07 billion in 2030 at a compound annual growth rate (CAGR) of 12.6% • Growth Driver: Cardiovascular Diseases Fueling Growth In The Anticoagulants Market • Market Trend: Innovative Factor Xa Tests Enhance Anticoagulant Effectiveness And Clinical Decision-Making • North America was the largest region in 2025.

What Is Covered Under Anticoagulants Market?

Anticoagulants refer to a drug used to prevent and treat blood clots in the heart and blood arteries. called a blood thinner as well. It is utilized to slow down the body's clotting process. These are blood thinners, but they do not thin the blood, instead, they avoid or minimize clots or thrombi. The main drug classes of anticoagulants are Factor Xa Inhibitor, Heparin & LMWH, Vitamin K Antagonist, and others. Factor Xa inhibitors are anticoagulants that inhibit clot formation by specifically and reversibly blocking the function of clotting factor Xa. The different routes of administration include oral anticoagulants, and injectable anticoagulants and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacy. It is used in venous thromboembolism, atrial fibrillation or flutter, coronary artery disease, and others and is used in hospitals, home care, specialty centers, and others.

What Is The Anticoagulants Market Growth Forecast?

The anticoagulants market size is expected to see rapid growth in the next few years. It will grow to $97.07 billion in 2030 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to growing atrial fibrillation population, expanding use of factor Xa inhibitors, improved safety profiles of NOACs, increasing outpatient anticoagulation management, rising adoption in emerging markets. Major trends in the forecast period include rising adoption of direct oral anticoagulants, shift from injectable to oral therapies, increasing long-term anticoagulation therapy use, growing focus on patient compliance and safety, expanding use in preventive cardiovascular care.

Global Anticoagulants Market Segmentation

1) By Drug Class: Factor Xa Inhibitor, Heparin And LMWH, Vitamin K Antagonist, Other Drug Classes 2) By Route Of Administration: Oral Anticoagulant, Injectable Anticoagulant 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 4) By Application: Venous Thromboembolism, Atrial Fibrillation Or Flutter, Coronary Artery Disease, Other Applications 5) By End User: Hospitals, Homecare, Specialty Centers, Other End-Users Subsegments: 1) By Factor Xa Inhibitor: Rivaroxaban, Apixaban, Edoxaban, Betrixaban 2) By Heparin And LMWH (Low Molecular Weight Heparin): Unfractionated Heparin, Enoxaparin, Dalteparin, Tinzaparin 3) By Vitamin K Antagonist: Warfarin, Acenocoumarol, Phenprocoumon 4) By Other Drug Classes: Direct Thrombin Inhibitors, Novel Oral Anticoagulants (NOACs)

What Is The Driver Of The Anticoagulants Market?

The increasing cardiovascular diseases are a key factor driving the growth of the anticoagulants market over the coming years. CVDs (cardiovascular diseases) are a category of heart and blood vessel problems. Cardiovascular diseases (CVDs) are the primary, source of death worldwide with low- and middle-income nations accounting for three-quarters of CVD deaths. Anticoagulation pharmacotherapy known as direct oral anticoagulants is used to minimize thrombosis in a variety of cardiovascular situations. For instance, in September 2025, according to the British Heart Foundation, a UK-based charity, across the UK, more than 7.6 million people over 4 million men and more than 3.6 million women are living with cardiovascular disease, and projections indicate that, driven by an aging population and improved survival rates, the number of affected individuals may rise by around 1 million by 2030 and by approximately 2 million by 2040. Therefore, the increasing number of cardiovascular diseases drive the growth of the anticoagulants industry.

Key Players In The Global Anticoagulants Market

Major companies operating in the anticoagulants market are GlaxoSmithKline plc, Leo Pharma A/S, Amphastar Pharmaceuticals Inc., Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Mylan N.V., Pfizer Inc., Sanofi S.A., Apotex Inc., Aspen Pharmacare Holdings Limited, AstraZeneca plc, Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Fresenius Kabi AG, Hikma Pharmaceuticals plc, Johnson & Johnson, Lupin Limited, Mitsubishi Tanabe Pharma Corporation, Natco Pharma Limited, Novartis International AG, Portola Pharmaceuticals Inc., Strides Pharma Science Limited, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Torrent Pharmaceuticals Limited, and Zydus Cadila Healthcare Limited.

Global Anticoagulants Market Trends and Insights

Major companies operating in the anticoagulants market are focusing on developing innovative solutions such as factor Xa inhibitor tests to meet the growing demand for testing due to the increased use of direct oral anticoagulants for stroke prevention and other serious cardiovascular conditions. Factor Xa Inhibitor Tests are assessments designed to evaluate the effectiveness and safety of anticoagulant medications that selectively inhibit factor Xa, thereby preventing blood clot formation in various medical conditions. For instance, in February 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based biotechnology company, launched apixaban, edoxaban, and rivaroxaban coagulation tests. These newly launched coagulation tests for Factor Xa inhibitors utilize Roche's innovative reagent cassette concept, ensuring high-quality results and efficient sample processing while also providing standardization and automation for better workflow in laboratories. These tests are significant as they support clinical decision-making in patients using direct oral anticoagulants for stroke prevention, addressing the rising global demand for effective diagnostics in managing serious conditions like coronary artery disease and peripheral arterial disease.

What Are Latest Mergers And Acquisitions In The Anticoagulants Market?

In April 2025, Novartis, a Switzerland-based provider of innovative pharmaceuticals and biologics, acquired Anthos Therapeutics for up to $3.1 billion. With this acquisition, Novartis aims to strengthen its position in the anticoagulant therapeutics landscape by advancing a late-stage Factor XI inhibitor with the potential to address significant unmet needs in thromboembolic disease management. Anthos Therapeutics is a US-based biopharmaceutical company developing monoclonal antibody–based anticoagulant therapies, including the Phase 3 investigational agent abelacimab for stroke prevention and cancer-associated thrombosis.

Regional Insights

North America was the largest region in the anticoagulants market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Anticoagulants Market?

The anticoagulants market consists of sales of rivaroxaban, dabigatran, apixaban, and edoxaban. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Anticoagulants Market Report 2026?

The anticoagulants market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the anticoagulants industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.